New research supports previous findings that selective serotonin reuptake inhibitors (SSRIs), a type of antidepressant medication, are associated with decreased mortality in patients with COVID-19. Using electronic health records from a population of more than 80,000 people diagnosed with COVID-19, researchers compared patients prescribed SSRIs with similar patients not treated with SSRIs. Relative risk of mortality was reduced for individuals taking any SSRI, those taking fluoxetine, and those taking either fluoxetine or fluvoxamine. Patients taking a specific SSRI other than fluoxetine or fluvoxamine did not experience statistically significant reductions in mortality risk. To learn more, see the study in JAMA.